Evonik Industries AG (EVKIY)
| Market Cap | 9.58B -9.1% |
| Revenue (ttm) | 15.82B -9.4% |
| Net Income | 181.02M -47.5% |
| EPS | 0.39 -47.6% |
| Shares Out | n/a |
| PE Ratio | 52.91 |
| Forward PE | 11.29 |
| Dividend | 0.44 (4.35%) |
| Ex-Dividend Date | May 30, 2025 |
| Volume | 126 |
| Average Volume | 2,021 |
| Open | 10.02 |
| Previous Close | 10.39 |
| Day's Range | 10.02 - 10.50 |
| 52-Week Range | 7.24 - 11.68 |
| Beta | 0.54 |
| RSI | 54.22 |
| Earnings Date | May 8, 2026 |
About Evonik Industries AG
Evonik Industries AG operates as a chemicals company in the Asia-Pacific, Europe, the Middle East, Africa, and the Americas. It operates through the Advanced Technologies, Custom Solutions, and Infrastructure segments. The Advanced Technologies segment provides polymers for medical applications; crosslinkers; hydrogen peroxide, a sterilizing agent for cleaning silicon wafers and a bleaching agent for the paper and textile industries; fumed and precipitated silicas and silanes for the automotive, tire, electronics, and cosmetics industries; and ... [Read more]
Financial Performance
In 2025, Evonik Industries AG's revenue was 14.07 billion, a decrease of -7.18% compared to the previous year's 15.16 billion. Earnings were 265.00 million, an increase of 19.37%.
Financial numbers in EUR Financial StatementsNews
Evonik Industries AG (EVKIF) Q1 2026 Earnings Call Highlights: Surpassing Expectations Amidst ...
Evonik Industries AG (EVKIF) Q1 2026 Earnings Call Highlights: Surpassing Expectations Amidst Challenges
Q1 2026 Evonik Industries AG Earnings Call Transcript
Q1 2026 Evonik Industries AG Earnings Call Transcript
Evonik Industries (EVKIF) Reports Q1 Revenue of $3.43B, Adjusted EBITDA Exceeds Expectations
Evonik Industries (EVKIF) Reports Q1 Revenue of $3.43B, Adjusted EBITDA Exceeds Expectations
Evonik Industries AG Earnings Call Transcript: Q1 2026
Q1 2026 adjusted EBITDA exceeded expectations at EUR 475 million, driven by strong Advanced Technologies and pre-buying effects, while free cash flow remained robust. Q2 EBITDA is guided to at least EUR 550 million, but risks from inflation and supply chain disruptions persist.
Evonik Q1 Results Slip On Forex Impact, Drop In Sales Volumes; Expects Q2 Adj. EBITDA To Rise
BRUSSELS (dpa-AFX) - Evonik Industries AG (EVK.DE), a German chemicals company, on Friday posted a decline in net income and sales for the first quarter of fiscal 2026.For the three-month period, ...
EQS-PVR: Evonik Industries AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Evonik Industries AG Evonik Industries AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-w...
EQS-DD: Evonik Industries AG: Lauren Kjeldsen, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 21.04.2026 / 10:39 CET/CEST The issuer is solely responsi...
Evonik Industries AG Earnings Call Transcript: Q4 2025
Delivered solid 2025 results with EUR 1.9 billion adjusted EBITDA and strong cash flow. 2026 guidance targets stable earnings amid persistent weak demand, cost savings, and a new flexible dividend policy. Regulatory and market changes, especially in methionine and Oxeno, will shape performance.
Evonik Industries AG Earnings Call Transcript: Q3 2025
Q3 results were weak, leading to a revised full-year EBITDA guidance of EUR 1.9 billion, but confidence remains in meeting targets due to strong healthcare and Animal Nutrition recovery. Structural cost savings, new plant ramp-ups, and the SYNEQT carve-out are expected to support future performance despite ongoing market challenges.
Evonik Industries AG Earnings Call Transcript: Q2 2025
Q2 results were resilient despite macro headwinds, with core segments stable and cost savings underway. Full-year guidance is maintained at the lower end, but achieving it depends on macro improvement and strict cost controls.
Evonik Industries AG Transcript: CMD 2025
A new group structure with two segments supports differentiated management and capital allocation, aiming for €1 billion additional EBITDA and 11% ROCE by 2027. Growth is driven by innovation, operational excellence, and targeted investments, with major portfolio steps and disciplined capital allocation.
Evonik Industries AG Earnings Call Transcript: Q1 2025
Q1 2025 saw EBITDA and free cash flow rise, with over 50% year-over-year EBITDA growth and record sales. Full-year guidance is confirmed, supported by strong specialty additives and nutrition and care segments, while risks from macroeconomic and trade factors persist.
Evonik Industries AG Earnings Call Transcript: Q4 2024
Delivered 25% EBITDA growth and strong free cash flow in 2024, with continued earnings growth expected in 2025 driven by cost savings, innovation, and robust segment performance. Market sentiment has improved, and a new segment structure will enhance business steering.
Evonik Industries AG Earnings Call Transcript: Q3 2024
Q3 2024 saw sector-leading earnings growth, a 15% EBITDA margin, and strong free cash flow, driven by cost savings and portfolio realignment. Specialty Additives and Silica segments posted robust volume growth, while outlook for 2025 remains positive with continued efficiency focus.
Evonik Industries AG Transcript: Status Update
Two new flexible epoxy curing agents, Ancamide 2853 and 2865, address market needs for high elongation, toughness, and eco-friendly profiles, with adjustable performance and fast cure times. Both are nonylphenol-free, contain bio content, and are available globally except Europe.
Evonik Industries AG Earnings Call Transcript: Q2 2024
Q2 2024 saw sector-leading earnings growth, strong free cash flow, and an upgraded EBITDA outlook. Focus remains on internal optimization, targeted investments, and disciplined capital allocation, with no M&A planned through 2025. Guidance reflects confidence despite macro uncertainties.
Evonik Industries AG Transcript: AGM 2024
The AGM highlighted a challenging year with declining sales and a negative net income, but strong free cash flow enabled a stable dividend. Strategic restructuring, cost reductions, and sustainability initiatives were emphasized, alongside new supervisory board members and continued investment in innovation.
Evonik Industries AG Earnings Call Transcript: Q1 2024
Evonik Industries AG Earnings Call Transcript: Q4 2023
Evonik to Cut 6% of Workforce
Evonik said it would cut up to 2,000 jobs by 2026, expecting cost reductions of around €400 million, after its fourth-quarter underlying earnings came in slightly below consensus forecasts.
Evonik says recovery unlikely in 2024, plans 2,000 job cuts
German chemicals group Evonik Industries said on Monday it expected no signs of a recovery in 2024 and announced up to 2,000 job cuts worldwide by 2026 in a bid to cut costs.
Germany's Economy Is in a Bad Slump. These 6 Stocks Could Rebound.
Look for companies that have been bearing the brunt of the pain to pull out stronger.